These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24781442)

  • 1. Dose and dosing frequency of long-acting injectable antipsychotics: a systematic review of PET and SPECT data and clinical implications.
    Uchida H; Suzuki T
    J Clin Psychopharmacol; 2014 Dec; 34(6):728-35. PubMed ID: 24781442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-sectional study of plasma risperidone levels with risperidone long-acting injectable: implications for dopamine D2 receptor occupancy during maintenance treatment in schizophrenia.
    Ikai S; Remington G; Suzuki T; Takeuchi H; Tsuboi T; Den R; Hirano J; Tsunoda K; Nishimoto M; Watanabe K; Mimura M; Mamo D; Uchida H
    J Clin Psychiatry; 2012 Aug; 73(8):1147-52. PubMed ID: 22967779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-acting injectable antipsychotics and the development of postinjection delirium/sedation syndrome (PDSS).
    Novakovic V; Adel T; Peselow E; Lindenmayer JP
    Clin Neuropharmacol; 2013; 36(2):59-62. PubMed ID: 23503549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia.
    Uchida H; Mamo DC; Kapur S; Labelle A; Shammi C; Mannaert EJ; Mann SW; Remington G
    J Clin Psychiatry; 2008 Aug; 69(8):1281-6. PubMed ID: 18642974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview.
    Correll CU; Kim E; Sliwa JK; Hamm W; Gopal S; Mathews M; Venkatasubramanian R; Saklad SR
    CNS Drugs; 2021 Jan; 35(1):39-59. PubMed ID: 33507525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
    Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
    J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating dopamine D₂ receptor occupancy for doses of 8 antipsychotics: a meta-analysis.
    Lako IM; van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2013 Oct; 33(5):675-81. PubMed ID: 23948784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review.
    Kurose S; Mimura Y; Uchida H; Takahata K; Kim E; Suzuki T; Mimura M; Takeuchi H
    J Clin Psychiatry; 2020 Jul; 81(5):. PubMed ID: 32726002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.
    Pilon D; Tandon N; Lafeuille MH; Kamstra R; Emond B; Lefebvre P; Joshi K
    Clin Ther; 2017 Oct; 39(10):1972-1985.e2. PubMed ID: 28919292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
    Aggarwal NK; Sernyak MJ; Rosenheck RA
    J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.
    Gentile S
    Pharmacotherapy; 2013 Oct; 33(10):1087-106. PubMed ID: 23776129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Converting oral to long-acting injectable antipsychotics: a guide for the perplexed.
    Meyer JM
    CNS Spectr; 2017 Dec; 22(S1):14-28. PubMed ID: 29350127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long acting injectable antipsychotics in the treatment of schizophrenia: a review of literature].
    Graffino M; Montemagni C; Mingrone C; Rocca P
    Riv Psichiatr; 2014; 49(3):115-23. PubMed ID: 25000887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone.
    Remington G; Mamo D; Labelle A; Reiss J; Shammi C; Mannaert E; Mann S; Kapur S
    Am J Psychiatry; 2006 Mar; 163(3):396-401. PubMed ID: 16513859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies.
    Kishimoto T; Nitta M; Borenstein M; Kane JM; Correll CU
    J Clin Psychiatry; 2013 Oct; 74(10):957-65. PubMed ID: 24229745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased cerebral blood flow after single dose of antipsychotics in healthy volunteers depends on dopamine D2 receptor density profiles.
    Selvaggi P; Hawkins PCT; Dipasquale O; Rizzo G; Bertolino A; Dukart J; Sambataro F; Pergola G; Williams SCR; Turkheimer F; Zelaya F; Veronese M; Mehta MA
    Neuroimage; 2019 Mar; 188():774-784. PubMed ID: 30553916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.
    Howes OD; Egerton A; Allan V; McGuire P; Stokes P; Kapur S
    Curr Pharm Des; 2009; 15(22):2550-9. PubMed ID: 19689327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia.
    Gefvert O; Eriksson B; Persson P; Helldin L; Björner A; Mannaert E; Remmerie B; Eerdekens M; Nyberg S
    Int J Neuropsychopharmacol; 2005 Mar; 8(1):27-36. PubMed ID: 15710053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.